<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30061276</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>08</Month>            <Day>08</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1791-7530</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>38</Volume>                    <Issue>8</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                    </PubDate>                </JournalIssue>                <Title>Anticancer research</Title>                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>            </Journal>            <ArticleTitle>Quality of Life Following Stereotactic Body Radiotherapy <i>Versus</i> Three-Dimensional Conformal Radiotherapy for Vertebral Metastases: Secondary Analysis of an Exploratory Phase II Randomized Trial.</ArticleTitle>            <Pagination>                <MedlinePgn>4961-4968</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.12814</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">This was a prespecified secondary analysis of a randomized trial, which analyzed quality of life (QOL), fatigue, and emotional distress following stereotactic body radiotherapy (SBRT) versus conventional three-dimensional conformal radiotherapy (3DCRT) as part of palliative management of painful spinal metastases.</AbstractText>                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Fifty-five patients were enrolled in this single-institutional randomized exploratory phase II trial (NCT02358720). Participants were randomly assigned to receive SBRT (single-fraction 24 Gy) or 3DCRT (30 Gy/10 fractions). QOL (EORTC QLQ-BM22), fatigue (EORTC QLQ FA13), and emotional distress (QSC-R10) at the end of radiotherapy, along with 3- and 6-month follow-up were assessed.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">At all recorded time points, there were no significant QOL differences between cohorts, including painful sites, pain characteristics, functional impairment, or psychosocial aspects (p&gt;0.05 for all). There were also no differences in all dimensions of fatigue between groups at each recorded time point (p&gt;0.05 for all). Emotional distress was also similar at three (p=0.248) and six months (p=0.603).</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although these results demonstrate that SBRT does not cause worse QOL deteriorations compared to 3DCRT, larger randomized investigations are recommended to corroborate these findings.</AbstractText>                <CopyrightInformation>Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Sprave</LastName>                    <ForeName>Tanja</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, University Hospital of Heidelberg, Heidelberg, Germany tanja.sprave@med.uni-heidelberg.de.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Verma</LastName>                    <ForeName>Vivek</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA, U.S.A.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Förster</LastName>                    <ForeName>Robert</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, University Hospital of Heidelberg, Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Schlampp</LastName>                    <ForeName>Ingmar</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, University Hospital of Heidelberg, Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bruckner</LastName>                    <ForeName>Thomas</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Biometry, University Hospital of Heidelberg, Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bostel</LastName>                    <ForeName>Tilman</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, University Hospital of Heidelberg, Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>El Shafie</LastName>                    <ForeName>Rami Ateayh</ForeName>                    <Initials>RA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, University Hospital of Heidelberg, Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nicolay</LastName>                    <ForeName>Nils Henrik</ForeName>                    <Initials>NH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, University Hospital of Heidelberg, Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, University Hospital of Freiburg, Freiburg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Debus</LastName>                    <ForeName>Jürgen</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, University Hospital of Heidelberg, Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rief</LastName>                    <ForeName>Harald</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, University Hospital of Heidelberg, Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>                <PublicationType UI="D003160">Comparative Study</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Greece</Country>            <MedlineTA>Anticancer Res</MedlineTA>            <NlmUniqueID>8102988</NlmUniqueID>            <ISSNLinking>0250-7005</ISSNLinking>        </MedlineJournalInfo>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName>                <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000072716" MajorTopicYN="N">Cancer Pain</DescriptorName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName>                <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007680" MajorTopicYN="N">Kidney Neoplasms</DescriptorName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010166" MajorTopicYN="N">Palliative Care</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016634" MajorTopicYN="N">Radiosurgery</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020266" MajorTopicYN="N">Radiotherapy, Conformal</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013125" MajorTopicYN="N">Spinal Neoplasms</DescriptorName>                <QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>                <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">Spine metastases</Keyword>            <Keyword MajorTopicYN="Y">fatigue</Keyword>            <Keyword MajorTopicYN="Y">palliative radiotherapy</Keyword>            <Keyword MajorTopicYN="Y">quality of life</Keyword>            <Keyword MajorTopicYN="Y">stereotactic body radiation therapy</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>31</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>11</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30061276</ArticleId>            <ArticleId IdType="pii">38/8/4961</ArticleId>            <ArticleId IdType="doi">10.21873/anticanres.12814</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>